AbbVie stock forecast: Rally attempts to clear $255.07 resistance after positive news flow

Traders Union
All News
Financial News
AbbVie jumps 3.08% today to $251.74

Highlights

AbbVie reported completed long-term trial data for Bimatoprost SR, strengthening confidence in its ophthalmology pipeline and product outlook.
A new advisory board for SkinMedica advances AbbVie's entry into aesthetics and regenerative medicine amid heightened institutional investment activity.
ABBV/USD shows bullish short- and long-term momentum, with price consolidation expected between $246.46 and $255.07 barring a support breakdown.

Pipeline developments and institutional flows deepen product-driven optimism

AbbVie's updated results from its long-term safety and efficacy extension trial for Bimatoprost SR, now completed for main clinical activities according to Tipranks, advance the company's ophthalmology pipeline and have likely deepened product-driven optimism. In parallel, the formation of a Regenerative Science Advisory Board for SkinMedica, as reported by Simplywall, positions AbbVie to strengthen its presence in the aesthetics and regenerative medicine market. Additional support comes from recent institutional activity, with the Illinois Municipal Retirement Fund increasing its position and Navigation Group LLC initiating a significant purchase, while some profit taking was observed from Midwest Professional Planners LTD., all cited by Themarketsdaily.

Overbought signals and mixed momentum as support holds above averages

On the H1 chart, ABBV is trading above the MA-20 at $246.04 and the MA-50 at $249.17. It also remains above the daily MA-200, set at $223.17. The Ichimoku Kijun line at $246.33 serves as immediate support. Short-term technical indicators are mixed: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both indicate prevailing sell pressure, while the Relative Strength Index (RSI) reads 52.62, with overbought conditions seen on both the Stochastic RSI and Bull/Bear Power, and a neutral Commodity Channel Index (CCI). The Awesome Oscillator currently signals selling pressure, suggesting a tug-of-war between bullish and bearish intraday forces.

Upside breakout favored as consolidation persists amid heightened volatility

Over the next several days, ABBV is anticipated to move within a projected range between $246.46 and $255.07, with volatility likely to remain heightened around current levels. There is a 61% probability of an upward breakout if resistance is breached, while a drop below the key support at $246.33 could trigger a bearish scenario, making downside moves less probable at 39%. Overall, the baseline expectation is for consolidation inside this corridor unless a breakout in either direction is triggered by fresh news or momentum.

Viktoras Karapetjanc, expert at Traders Union, sees solid fundamental momentum supporting AbbVie at current levels. He notes strong institutional flows and highlights the significance of recent clinical milestones and strategic moves in regenerative medicine. Karapetjanc believes consolidated price action above key support is constructive in the near term. "With product pipeline progress and institutional demand aligning, I expect ABBV to remain resilient — a breakout above $255.07 could unlock new upside opportunities."

Earlier, analysts noted that AbbVie was exhibiting a strong bullish structure but anticipated a period of sideways consolidation driven by mixed technical signals and overbought conditions. The latest surge in price, combined with new clinical and strategic developments, strengthens the bullish outlook, making the $255.07 resistance a pivotal level to monitor for a potential breakout in the current trading environment.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.